Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …

Opinion statement For the vast majority of patients diagnosed with follicular lymphoma, the
disease is never cured. As a result, it becomes a “chronic disease” that must be managed …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in
North America. Because of the heterogeneity of the disease, treatment options vary from …

Chemotherapy combinations have been the backbone of therapy for follicular lymphoma,
and are associated with high initial response rates. Unfortunately, toxicity and secondary …

Follicular lymphoma (FL) is the second most common lymphoma, and by virtue of its
chronicity, may be the most prevalent and most treated lymphoma in the United States …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin's lymphoma in northern
America. FL is an incurable disease with relapsing–remitting courses requiring serial …

Few topics in the field of hematology/oncology have generated as much controversy and
debate in the last 40 years as the proper management of patients with follicular non-Hodgkin …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …

The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …